Article
Ars Technica
(2018)
Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
Summit
updated 7 days ago
Comments
Related Chunks
Related chunks with this resource
Challenges of Health Care Innovation and Investing
RELATED RESOURCES
with chunks in common
2017
Is M&A the Cure for a Failing Health Care System? | Harvard Business Review
Saved by: Summit
1 chunk
2018
a16z Podcast: The Infrastructure of Total Health – Andreessen Horowitz
Saved by: Summit
2 chunks
2019
Death by a Thousand Clicks: Where Electronic Health Records Went Wrong | Fortune
Saved by: Summit
2 chunks
2020
Our personal health history is too valuable to be harvested by the tech giants
Saved by: Summit
3 chunks
2020
Veteran healthcare VC Camille Samuels explains why trying to cure infectious disease is a lousy business
Saved by: Summit
2 chunks
2020
Opinion | In the Race for a Coronavirus Vaccine, We Must Go Big. Really, Really Big. - The New York Times
Saved by: Summit
2 chunks
2020
Innovation, Manufacturing and Policy: Why tech didn’t save us from covid-19
Saved by: Summit
3 chunks
2022
HealthTech: Selling to SMBs, a Founder's Playbook | a16z Andreessen Horowitz
Saved by: Summit
3 chunks
No comments yet. Be the first to comment!